MTND2P20

Across TCGA pan-cancer cohorts, MTND2P20 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTND2P20 data layer.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MTND2P20 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND2P20 expression acts as an unfavorable survival marker, although some lineages such as KICH and STAD show a favorable association.

ESCA, THCA, and UCS are the cancer types where MTND2P20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Quartile	All	0.237	0.829	.001	49	view →
THCA	DFS	Tertile	IV	0.358	0.914	<.001	48	view →
UCS	OS	Tertile	III,IV	0.001	0.594	<.001	36	view →
KICH	OS	Tertile	II,III,IV	1.000	0.716	.021	31	view →
UCEC	DFS	Tertile	All	0.449	0.712	.003	24	view →
LGG	OS	Tertile	All	0.834	0.914	.012	24	view →
KIRC	DFS	Tertile	II,III,IV	0.429	0.684	.024	18	view →
STAD	DFS	Median	IV	0.503	0.152	.006	9	view →
ACC	DFS	Tertile	All	1.000	0.432	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MTND2P20–ESCA (DFS)

Open the ESCA breakdown →